Ariad, MolecularMD Partner on Companion Dx for T315I Mutation

MolecularMD has done BCR-ABL mutation testing with its standardized and validated sequencing test in patients enrolled in Ariad's earlier Phase 1 trial of ponatinib and is currently engaged in testing patients prior to treatment in the PACE trial.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories